Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE. · 2018

Read Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. by Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5987416.txt.

Introduction

Holmgaard and co-authors test the TGF-beta pathway blocker galunisertib as a booster of antitumour immunity. Their study appeared in the Journal for Immunotherapy of Cancer. TGF-beta helps tumours grow, spread, and hide from immunity. Blocking its immune effects may lift immunotherapy results. Galunisertib is a small molecule inhibitor in clinical testing. The team used cell work and mouse tumour models. Doses matched those used in patients.

The drug freed human T cells from suppression in vitro, they report. In mice it nearly halted tumour growth in a dose-linked way. Half the animals cleared their tumours for good. Pairing it with PD-L1 blockade improved results further.

Catalog record

CREATORHolmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5987416

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade By Rikke B Holmgaard, David A Schaer, Yanxia Li, Stephen P Castaneda, Mary Y Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R Manro, Philip W Iversen, David Surguladze, Gerald E Hall Published in: Journal for Immunotherapy of Cancer DOI: 10.1186/s40425-018-0356-4 ABSTRACT Abstract Background TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance. Inhibiting TGFβ’s immune suppressive effects has become of particular interest as a way to increase the benefit of cancer immunotherapy. Here we utilized preclinical models to explore the impact of the clinical stage TGFβ pathway inhibitor, galunisertib, on anti-tumor immunity at clinically relevant doses. Results In vitro treatment with galunisertib reversed TGFβ and regulatory T cell mediated suppression of human T cell proliferation. In vivo treatment of mice with established 4T1-LP tumors resulted in strong dose-dependent anti-tumor activity with close to 100% inhibition of tumor growth and complete regressions upon cessation of treatment in 50% of animals. This effect was CD8+ T cell dependent, and led to increased T cell numbers in treated tumors. Mice with durable regressions rejected tumor rechallenge, demonstrating the establishment of immunological memory. Consequently, mice that rejected immunogenic 4T1-LP tumors were able to resist rechallenge with poorly immunogenic 4 T1 parental cells, suggesting the development of a secondary immune response via antigen spreading as a consequence of effective tumor targeting. Combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition and complete regressions in colon carcinoma models, demonstrating the potential synergy when cotargeting TGFβ and PD-1/PD-L1 pathways. Combination therapy was associated with enhanced anti-tumor immune related gene expression profile that was accelerated compared to anti-PD-L1 monotherapy. Conclusions Together these data highlight the ability of galunisertib to modulate T cell immunity and the therapeutic potential of combining galunisertib with current PD-1/L1 immunotherapy. Keywords: TGF-β receptor I, Antitumor efficacy, Checkpoint inhibitors, Galunisertib BACKGROUND Transforming growth factor-beta (TGFβ) has been identified as a therapeutic target in cancer because of its significant and varied roles to promote tumor growth, survival, and metastasis. There are several pharmacological approaches to block TGFβ signaling, including neutralizing antibodies, vaccines, antisense oligonucleotides and small molecular inhibitors (SMI) [1, 2]. The goal of these therapies is to block the tumor-promoting effects of TGFβ, while maintaining its tumor suppressive properties. Emerging data and thought suggest that the efficacy of TGFβ antagonist therapy in cancer might not only derive from direct intrinsic effects on tumor cells, but also involves tumor extrinsic mechanisms acting in the tumor micro-environment. TGFβ plays pleiotropic roles to initiate and progress cancer including both tumor cell intrinsic and extrinsic activities. Tumor cell intrinsic activities of the TGFβ pathway include autocrine TGFβ driven tumor cell proliferation and differentiation, epithelial to mesenchymal transition (EMT), invasion and migration, prometastatic cytokine production, and autocrine mitogen production [3, 4]. Tumor cell extrinsic activities include promoting of increased tumor vascularization, modulation of the stromal extracellular matrix, induction of and feedback modulation of the hypoxic state and inhibition of immune surveillance and antitumor immunity [4, 5]. Systemic TGFβ ligand levels are often elevated in cancer patients compared to healthy individuals, and increased ligand levels have been further associated with aggressive disease and poor prognosis [6, 7]. Elevated TGFβ ligand levels are observed in patients whose tumor cells are both sensitive (i.e. receptor positive, TGFβ ligand dependent) or insensitive (i.e receptor negative, TGFβ ligand independent) to TGFβ signaling. Furthermore, aberrant TGFβ signaling has been implicated in several human diseases, including malignancies such as glioblastoma and breast cancer [8–10]. TGFb additionally plays a non-redundant, crucial role in regulating immunity. TGFβ is produced by a number of immune cells and plays an essential role in the regulation of immune responses and immune tolerance [4, 11]. Genetic deletion and antibody neutralization studies have demonstrated that TGFβ inhibition enhances T cell [12] and NK cell differentiation and function [13], suggesting that pharmacologic inhibition of TGFβ signaling might decrease the suppression of host immune surveillance. Furthermore, deletion of TGFβ signaling in myeloid cells has been shown to enhance their anti-tumorigenic properties [14]. The immunological consequences of TGFβ antagonism are particularly relevant in the context of anti-tumor immunotherapy, and blockade of the TGFβ pathway has become an attractive approach to inhibit the multitude effects the TGFβ pathway has on cancer progression and anti-tumor immunity. That TGFβ may be involved in the maintenance of self-tolerance and pathogenesis of systemic inflammatory diseases is indicated in studies which show the development of multi-organ inflammation in Tgfb1−/− mice [15, 16]. The inflammation in Tgfb1−/− mice is dependent on T cells, which undergo massive activation [17]. Generation of mice lacking TGFβRII specifically on T-cells further demonstrates the importance of TGFβ in regulating T-cell responses in vivo, as mice develop multi-organ inflammation similar to that seen in TGFβ1−/− mice [12, 18]. In addition to the direct effects on effector T cell responses, TGFβ can promote immunosuppression via direct induction and modulation of regulatory T cells (Tregs) [19]. TGFβ directly promotes expression of Foxp3 in CD4+ T-cells, converting them to a regulatory phenotype [20]. In addition to induction and maintenance of Foxp3 expression, TGFβ has also been shown to be important in the functional ability of Tregs to suppress immune responses [21, 22], and it has been demonstrated that Tgfb1−/− mice fail to maintain peripheral Treg cells [21]. TGFβ1-producing myeloid-derived suppressor cells (MDSCs) have also been reported at high levels in the tumor microenvironment [23, 24]. Clinical studies have provided proof of concept data supporting the role of TGFβ in cancer and the utility of targeting the TGFβ pathway [1]. Galunisertib (LY2157299 monohydrate) is an oral small molecule inhibitor (SMI) of the TGFβ receptor I (TGFβRI) kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway [1] (Yingling et al., [25]). By targeting TGFβRI, signaling via all three TGFβ ligands is blocked [1]. Galunisertib demonstrates the ability to inhibit TGFβ-dependent tumor cell intrinsic and extrinsic functions in vitro and in vivo, and to inhibit tumor-cell growth in established tumor mouse models (Yingling et al., [25]). Galunisertib is currently under clinical development in combination with checkpoint inhibitors (including nivolumab and durvalumab) in patients with NSCLC, HCC, or pancreatic cancer (NCT02423343; NCT02734160). In the current study, we set out to characterize in detail the impact of galunisertib-mediated TGFβR1 blockade on anti-tumor immunity. Using both in vitro and in vivo model systems, we show that galunisertib enhances the development of anti-tumor T cell immunity through modulating both effector and regulatory T cell function. Using an immunogenic 4 T1-LP breast tumor model, we show that galunisertib mediates robust anti-tumor T cell immunity and promotes the establishment of T cell memory and antigen spreading. Using in vitro assays and primary human Treg cells we show that Galunisertib treatment blocks the suppressive activity of human Tregs, further highlighting its important role in T cell immunity. The TGFβ pathway was recently described as a potential mechanism of resistance for anti-PD-1/L1 checkpoint blockade [26, 27]. To this end, we show that galunisertib treatment at a clinically relevant dose enhances the anti-tumor activity of anti-PD-L1 resulting in

Read the complete text